Physician profile
Matthew D Cole
NPI 1942487343
$842.07
in general payments reported to CMS, 2019-2025
17 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $91.68 · 2021: $18.42 · 2022: $141 · 2023: $114 · 2024: $117 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solta Medical, A Division of Bausch Health US, LLC | $129.27 | 2022-2025 | |
| Stemline Therapeutics INC. | $86.05 | 2019 | |
| Pfizer INC. | $84.88 | 2019-2025 | |
| Mauna Kea Technologies, INC. | $82.01 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $70.77 | 2020-2023 | Dupixent |
| Janssen Biotech, INC. | $69.71 | 2022 | |
| Genzyme Corporation | $52.88 | 2019-2020 | |
| Biofrontera INC. | $41.80 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Sun Pharmaceutical Industries INC. | $33.20 | 2022 | |
| Amgen INC. | $31.61 | 2024 | Otezla |
| Sensus Healthcare, INC. | $30.04 | 2024 | |
| Galderma Laboratories, L.P. | $28.63 | 2019-2022 | |
| Abbvie INC. | $27.44 | 2025 | |
| Vyne Pharmaceuticals INC. | $19.85 | 2020 | |
| Allergan, INC. | $18.42 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.14 | 2024 | Cologuard Collection Kit |
| Verrica Pharmaceuticals INC. | $17.37 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.